Hidradenitis suppurativa in the elderly: new insights

White, Jonathan M; Del Marmol, Véronique

doi:10.1093/bjd/ljad378

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Specifically, most patients (76%) present with early-onset HS, peaking at 17 years of age, while a smaller proportion of individuals develop late-onset HS, peaking at around 40 years of age [5]. Geriatric HS, defined as the persistence of active disease beyond the age of 65 years or the development of HS occurring after that age, has been poorly investigated, with only a few case reports and cohort studies published so far [6][7][8][9][10][11]. The aim of this multicentric, retrospective study was to investigate the clinical features of HS in elderly subjects and to identify peculiar aspects related to treatment management and response to therapies.…”

Section: Introductionmentioning

confidence: 99%

Clinical Features and Response to Treatment in Elderly Subjects Affected by Hidradenitis Suppurativa: A Cohort Study

Antonelli,

Ippoliti,

Rosi

et al. 2023

JCM

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic-relapsing inflammatory skin disease. It usually appears in the second and third decades, but a smaller proportion of patients develop late-onset HS. Geriatric HS, defined as the persistence or the development of HS after the age of 65 years, has been poorly explored. This study aimed to investigate the clinical features, treatment management and response to therapies of HS elderly subjects (≥65 years old). We designed a multicentric observational study, gathering data from seven Italian university hospitals. Demographic and clinical data of HS patients aged over 65 years were collected at baseline, week 12 and week 24. Overall, 57 elderly subjects suffering from HS were enrolled. At baseline, disease severity was predominantly moderate-to-severe, with 45.6% of patients classified as Hurley III. The gluteal phenotype was the most frequently observed; it also appeared to affect patients’ quality of life more than other phenotypes. Gluteal involvement was detected in about half (49.1%) of cases and associated with severe stages of the disease. In terms of therapeutic response, Hurley III patients showed the persistency of higher values of mean IHS4, DLQI, itch- and pain-NRS scores compared to Hurley I/II. In conclusion, disease severity in this subpopulation appears high and treatment is often challenging.

show abstract